［1］Coates AS，Winer EP，Goldhirsch A，et al.Tailoring therapies improving the management of early breast cancer：St gallen international expert consensus on the primary therapy of early breast cancer 2015［J］.Ann Oncol，2015，26(8)：1533-1546.
［2］Ma X，Jin Z，Li G，et al.Classification of chronic radiation-induced ulcers in the chest wall after surgery in breast cancers［J］.Radiation Oncology，2017，12(1)：135.
［3］ LIAN Zhenqiang，HE Jiehua,WANG Xi,et al.Clinical features and survival analysis of molecular subtyping of breast cancer［J］.Chinese Journal of Breast Disease(Electronic Version),2009,3(2):139-146.［连臻强,何洁华,王曦,等.乳腺癌不同分子亚型的临床特点和生存分析［J］.中华乳腺病杂志（电子版），2009, 3(2):139-146.］
［4］Poortmans PM，Collette S，Kirkove C，et al.Internal mammary and medial supraclavicular irradiation in breast cancer［J］.N Engl J Med，2015(373)：317-327.
［5］Kirova YM，Carroll S，Fourquet A，et al.The St gallen international expert consensus on the primary therapy of early breast cancer 2017：The point of view of an international panel of experts in radiation oncology［J］.Annals of Oncology，2018，29(1)：280-281.
［6］Chandra RA，Miller CL，Skolny MN，et al.Radiation therapy risk factors for development of lymphedema in patients treated with regional lymph node irradiation for breast cancer［J］.Int J Radiat Oncol Biol Phys，2015(91)：760-764.
［7］Kneubil MC，Brollo J，Botteri E，et al.Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction［J］.Eur J Surg Oncol，2013(39)：260-265.
［8］Oh H，Eliassen AH，Wang M，et al.Expression of estrogen receptor，progesterone receptor，and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer［J］.Breast Cancer，2016(2)：16032.
［9］Jeon-Hor C，Yang Z，Siwa C，et al.Quantitative analysis of peri-tumor fat in different molecular subtypes of breast cancer［J］.Magnetic Resonance Imaging，2018(53)：34-39.
［10］Tseng YD，Uno HU，Hughes ME，et al.Biological subtype predict risk of locoregional recurrence after mastectomy and impact of postmastectomy radiation in a large national database［J］.Int J Radiat Oncol Biol Phys，2015，93(3)：622-630.
［11］Liu FF，Shi W，Done SJ，et al.Identification of a low-risk luminal a breast cancer cohort that may not benefit from breast radiotherapy［J］.J Clin Oncol，2015(33)：2035-2040.
［12］Fehrenbacher L，Capra AM，Quesenberry Jr CP，et al.Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006：a cohort from an integrated health care delivery system［J］.J Clin Oncol，2014，32(20)：2151-2158.
［13］Wen G，Zhang JS，Zhang YJ，et al.Predictive value of molecular subtyping for locoregional recurrence in early-stage breast cancer with N1 without postmastectomy radiotherapy［J］.J Breast Cancer，2016，19(2)：176-184.
［14］Bartelink H，Maingon P，Poortmans P，et al.European organisation for research and treatment of cancer radiation oncology and breast cancer groups.Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer：20-year follow-up of a randomised phase 3 trial［J］.Lancet Oncol，2015，16(1)：47-56.
［15］Torres-Roca JF，Fulp WJ，Caudell JJ，et al.Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer［J］.Int J Radiat Oncol Biol Phys，2015，93(3)：631-638.
［16］Whelan TJ，Pignol JP，Levine MN，et al.Longterm results of hypofractionated radiation therapy for breast cancer［J］.N Engl J Med，2010(362)：513-520.
［17］Haviland JS，Owen JR，Dewar JA，et al.The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionaction for treatment of early breast cancer：10-year follow-up results of two randomised trials［J］.Lancet Oncol，2013(14)：1086-1094.
［18］Bane AL，Whelan TJ，Pond GR，et al.Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy［J］.Ann Oncol，2014(25)：992-998.
［19］Brown LC，Diehn FE，Boughey JC，et al.Delineation of supraclavicular target volumes in breast cancer radiation therapy［J］.Int J Radiat Oncol Biol Phys，2015(92)：642-649.
［20］Correa C，Harris EE，Leonardi MC，et al.Accelerated partial breast irradiation：Executive summary for the update of an ASTRO evidence-based consensus statement［J］.Pract Radiat Oncol，2017，7(2)：73-79.
［21］Veronesi U，Orecchia R，Maisonneuve P，et al.Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT)：A randomised controlled equivalence trial［J］.Lancet Oncol，2013，14(13)：1269-1277.
［22］Wilke CM，Hess J，Klymenko SV，et al.Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer［J］.International Journal of Cancer，2018，142(3)：573-583.
［23］Pashtan JM，Recht A，Ancukiewicz M，et al.External beam accelerated partial breast irradiation using 32 Gy in 8 twice-daily fractions：5-year results of a prospective study［J］.Int J Radiat Oncol Biol Phys，2012(84)：271-277.
［24］Wilkinson JB，Shah C，Amin M，et al.Outcomes according to breast cancer subtype in patients treated with accelerated partial breast irradiation［J］.Clin Breast Cancer，2017，17(1)：55-60.
［25］Hughes KS，Schnaper LA，Bellon JR，et al.Lumpectomy plus tamoxifen with or without irradiation in women aged 70 years or older with early breast cancer：Long-term follow-up of CALGB 9343［J］.J Clin Oncol，2013，31(19)：2382-2387.
［26］Kunkler IH，Williams LJ，Jack WJ，et al.Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breasr cancer (PRIME II)：A randomised controlled trial［J］.Lancet Oncol，2015，16(3)：266-273.
［27］Williams KE，Barnes NL，Cramer A，et al.Molecularphenotypes of DCIS predict overall and invasive recurrence［J］.Ann Oncol，2015(26)：1019-1025.
［28］Radi DMA，Abd-Elazeem MA.The utility of ThinPrep cytology and immunohistochemical staining of p16INK4a，Ki-67，and p63 in the assessment of cervical intraepithelial neoplasia (dysplasia)［J］.Egyptian Journal of Pathology，2017，37(1)：209-219.
［29］Curigliano G，Disalvatore D，Esposito E，et al.Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ［J］.Ann Oncol，2015，26(4)：682-687.
［30］Lazzeroni M，Dunn BK，Pruneri G，et al.Adjuvant therapy in patients with ductal carcinoma in situ of the breast：the Pandora's box［J］.Cancer Treat Rev，2017（55）：1-9.